Ryuji Yamamoto
Kobe, 6590021, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Translational applicability of human blood-brain barrier spheroid models for the development of brain-penetrant therapeutic antibodies.
Journal: Fluids and barriers of the CNS
Published: August 26, 2025
Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice.
Journal: Molecular therapy. Methods & clinical development
Published: February 16, 2023
Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses.
Journal: International journal of molecular sciences
Published: September 07, 2022
Pharmacokinetics and pharmacodynamics of once-weekly administration of JR-142, a long-acting albumin-fused human growth hormone: A rondemized, placebo-controlled phase 1 study.
Journal: Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
Published: April 14, 2022
Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice.
Journal: Molecular therapy. Methods & clinical development
Published: February 17, 2022
Pharmacological property, mechanism of action and clinical study results of Pabinafusp Alfa (Genetical Recombination) (IZCARGO® I.V. Infusion 10 mg) as the therapeutic for Mucopolysaccharidosis type-II (Hunter syndrome)
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: January 04, 2022
Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II.
Journal: Molecular genetics and metabolism reports
Published: April 12, 2021
Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: August 16, 2020
Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: Phase I and II/III clinical studies.
Journal: Molecular genetics and metabolism
Published: February 14, 2020
Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa.
Journal: PloS one
Published: December 25, 2019
Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease.
Journal: Molecular genetics and metabolism
Published: July 17, 2018
Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
Journal: Molecular genetics and metabolism
Published: March 07, 2018
Last Updated: 09/26/2026